PEG-MGF
Pegylated Mechano Growth Factor - the stabilised, long-acting form of MGF with a dramatically extended half-life, enabling subcutaneous administration and sustained satellite cell activation.
Community Rating
No ratings yet
Compound Profile
PEG-MGF
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. PEG-MGF is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Extended half-life (48-72 hours) vs. native MGF (minutes) - transforms MGF into a practical research tool
- Can be administered subcutaneously - no need for intramuscular injection into target tissue
- Sustained satellite cell activation across multiple days from a single injection
- PEG-MGF is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Extended half-life (48-72 hours) vs. native MGF (minutes) - transforms MGF into a practical research tool
- Can be administered subcutaneously - no need for intramuscular injection into target tissue
- Sustained satellite cell activation across multiple days from a single injection
- Promotes muscle hypertrophy by upregulating myoblast proliferation over an extended window
In Plain English
Simple summaryPEG-MGF is mechano growth factor that's been pegylated -- polyethylene glycol chains are attached to the peptide to protect it from rapid enzymatic degradation. Plain MGF has a plasma half-life measured in minutes; PEG-MGF extends that to several days. The modification doesn't change what MGF does, only how long it stays in circulation to do it. MGF activates muscle satellite cells -- the stem cells that repair and grow muscle -- and the E-domain peptide at MGF's C-terminus is the functional part that does this. The interest in PEG-MGF in research protocols stems from this extended half-life: a single injection can maintain circulating MGF-like activity for several days rather than requiring near-continuous administration.
- Extended half-life (48-72 hours) vs. native MGF (minutes) - transforms MGF into a practical research tool
- Can be administered subcutaneously - no need for intramuscular injection into target tissue
- Sustained satellite cell activation across multiple days from a single injection
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is PEG-MGF?
Tap any underlined term for an instant definition.
PEG-MGF (Pegylated Mechano Growth Factor) is the chemically modified, stable form of MGF created by attaching polyethylene glycol (PEG) polymer chains to the native MGF molecule. This pegylation process dramatically alters the pharmacokinetics: while native MGF is degraded within minutes in serum, PEG-MGF maintains a half-life of 48-72 hours - a transformation that makes it a far more practical research tool.
Pegylation is a well-established pharmaceutical technique used to extend the half-life of biologically active molecules. The PEG chains create a molecular "shield" around the MGF peptide, protecting it from enzymatic degradation and renal clearance. The increase in molecular size from PEG attachment also slows distribution and excretion. The result is a molecule that retains the biological activity of native MGF while becoming systemically available after subcutaneous injection.
This shift from local to systemic action has important implications for research. Native MGF acts only in the muscle where it is produced or injected - it reaches satellite cells in that specific tissue before being degraded. PEG-MGF, injected subcutaneously, distributes systemically, potentially reaching all muscle groups simultaneously. This makes it more practical for research into systemic muscle maintenance, sarcopenia, or recovery from generalised muscle damage.
The research value of PEG-MGF lies primarily in its role in satellite cell biology. Satellite cells are the regenerative stem cell pool of skeletal muscle - they remain quiescent until activated by MGF following mechanical stress or damage. PEG-MGF's extended half-life allows sustained activation of these cells over days rather than the brief window provided by endogenous MGF. This sustained activation is hypothesised to drive greater myoblast proliferation before the subsequent differentiation phase.
PEG-MGF is most commonly researched in combination with IGF-1 LR3 - a logical pairing because the two peptides target sequential steps in satellite cell biology. PEG-MGF activates and proliferates satellite cells; IGF-1 LR3 (via IGF-1 receptor signalling) drives their differentiation into mature muscle fibres. Research into this sequential protocol has been particularly active in the sports science and muscle hypertrophy research community.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on PEG-MGF. See all Muscle & Performance peptides for comparison.
Common Stacks
PEG-MGF is frequently combined with the following peptides for synergistic effects. Click any peptide to compare profiles before deciding.
The foundational GHRH+GHRP synergy stack: sermorelin primes pituitary GHRH receptors while Ipamorelin delivers a clean GH pulse.
Both are GHRH analogs with different half-lives; some researchers prefer sermorelin's shorter action for more physiological pulsatility.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
PEG-MGF research protocols typically use 200-400 mcg 2-3 times per week. Unlike native MGF, post-workout timing is recommended but not strictly required given the extended half-life.
Standard research dose: 200-400 mcg per injection Frequency: 2-3 times per week Administration: subcutaneous Common protocol: administer 2-3 times per week; follow with IGF-1 LR3 at 40-80 mcg on same days for synergistic satellite cell activation and differentiation
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Reconstitute with bacteriostatic water. Unlike native MGF, PEG-MGF can be administered subcutaneously into the abdomen or outer thigh. Rotate injection sites. Store reconstituted solution at 2-8 degrees C for up to 30 days.
What the research doesn't show
Pegylation solves the half-life problem but introduces its own questions. PEG accumulation in tissue is a documented phenomenon with pegylated biologics, and the long-term effects of PEG residues aren't fully characterized. Additionally, most PEG-MGF research is still preclinical -- human data is essentially absent, and the satellite cell activation in humans from injected PEG-MGF hasn't been directly measured.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain PEG-MGF, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
PEG-MGF has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: extended half-life (48-72 hours) vs. native mgf (minutes) - transforms mgf into a practical research tool.
The most commonly reported side effect in research subjects is injection site reactions - redness and swelling more common than with peptides injected im. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Plain MGF degrades too quickly to be useful as an injected compound. IGF-1 LR3 acts globally through systemic IGF-1 receptors; PEG-MGF is specifically aimed at the local satellite cell activation pathway via the E-domain. Most muscle repair protocols in research settings choose between IGF-1 LR3 for systemic anabolic signaling or PEG-MGF for satellite cell activation -- they're often combined because they target different aspects of muscle growth.
Compare PEG-MGF side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.